MedPath

Effect of frailty on prognosis in patients with metastatic prostate cancer(FRA-PmC study)

Not Applicable
Conditions
metastatic prostate cancer
Registration Number
JPRN-UMIN000039864
Lead Sponsor
Hirosaki University School of Medicine
Brief Summary

The overall survival was significantly shorter in patients with G8 <13 than that of>=13.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
96
Inclusion Criteria

Not provided

Exclusion Criteria

Not eligible for the standard of care

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome was the effect of frailty on progression-free survival in patients mHNPC and mCRPC.
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes included safety, overall survival.
© Copyright 2025. All Rights Reserved by MedPath